These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 8191943)

  • 1. [Inhibition of tumor cell growth by the action of high-energy sources].
    Rosell D; Robles JE; Abad JI; Agúera LG; De Castro F; Zudaire JJ; Berián JM
    Actas Urol Esp; 1993 Sep; 17(8):487-90. PubMed ID: 8237526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The enhancement of the chemotherapeutic effects on human prostate cancer cell--the combination with the growth factor interaction inhibitor (suramin)].
    Suzuki Y; Miwa Y; Akino H; Fujita T; Saikawa S; Kanimoto Y; Okada K
    Hinyokika Kiyo; 1993 Dec; 39(12):1215-20. PubMed ID: 8285172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin.
    Palayoor ST; Bump EA; Teicher BA; Coleman CN
    Radiat Res; 1997 Aug; 148(2):105-14. PubMed ID: 9254728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Shockwave cytotoxicity on neoplastic and non-neoplastic cells].
    Rosell D; Robles JE; Abad JI; Agüera LG; De Castro F; Zudaire JJ; Berían JM
    Actas Urol Esp; 1993 Jul; 17(7):412-4. PubMed ID: 8368113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Arah IN; Dixon SC; Horti J; Figg WD
    Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potentiation of cytotoxicity of electromagnetic shock waves by suramin, "in vitro" study].
    Rosell D; Robles JE; Aguera L; Abad JI; Rodríguez-Rubio FI; Zudaire JJ; Berian JM
    Actas Urol Esp; 1994 Jan; 18(1):29-33; discussion 34. PubMed ID: 8191943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
    LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
    Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suramin.
    Eisenberger MA; Sinibaldi V; Reyno L
    Cancer Pract; 1995; 3(3):187-9. PubMed ID: 7599677
    [No Abstract]   [Full Text] [Related]  

  • 10. Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors.
    Scher HI; Heston WD
    Cancer Treat Res; 1992; 59():131-51. PubMed ID: 1347690
    [No Abstract]   [Full Text] [Related]  

  • 11. [Suramin: pharmacology and antitumor effectiveness of an old parasiticide].
    Rebollo J
    Med Clin (Barc); 1994 Mar; 102(8):301-5. PubMed ID: 8170229
    [No Abstract]   [Full Text] [Related]  

  • 12. Suramin: a new therapeutic concept.
    Armand JP; Cvitkovic E
    Eur J Cancer; 1990 Apr; 26(4):417-9. PubMed ID: 2141503
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.